- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT07242872
Dépendance aux écrans et douleur postopératoire
Association entre l'addiction au smartphone et la douleur postopératoire et la consommation d'analgésiques chez les patients adultes subissant une rhinoplastie élective : une étude observationnelle prospective
Excessive or problematic smartphone use has become increasingly common and has been associated with various psychological and physical health consequences, including anxiety, depressive symptoms, reduced sleep quality, musculoskeletal pain, and heightened pain perception. Postoperative pain is influenced not only by surgical trauma but also by individual psychological and behavioral characteristics. This prospective observational study aims to investigate whether smartphone addiction levels influence postoperative pain scores and analgesic consumption in patients undergoing elective rhinoplasty surgery.
Aperçu de l'étude
Statut
Les conditions
Description détaillée
Problematic smartphone use-often referred to as smartphone addiction-has emerged as a significant behavioral concern worldwide. Prior research has demonstrated associations between excessive smartphone use and anxiety, depression, sleep disturbances, impaired attention, and increased musculoskeletal discomfort. Moreover, psychological factors such as stress, anxiety, and cognitive attention patterns are known to modulate postoperative pain perception.
Individuals with higher levels of smartphone addiction commonly exhibit elevated anxiety, restlessness, and depressive symptoms, which may heighten pain sensitivity and interfere with postoperative pain coping mechanisms. However, current literature includes limited evidence directly examining the relationship between smartphone addiction and postoperative pain outcomes.
This single-center prospective observational study will include adult patients aged 18-45 years undergoing elective rhinoplasty surgery under general anesthesia. Eligible participants will be ASA physical status I-II and without psychiatric disorders, chronic analgesic or psychotropic medication use, communication difficulties, prior rhinoplasty surgery, or additional concurrent surgical procedures.
Preoperative data collection will include demographic variables (age, sex, education level, duration of daily smartphone use). Participants will complete two validated instruments in Turkish: The Smartphone Application-Based Addiction Scale - Turkish Version, The Nomophobia Questionnaire (NMP-Q) - Turkish Version.
Surgical and anesthesia management will follow standardized institutional protocols. Postoperative pain will be assessed using the Visual Analog Scale (VAS) at 1, 6, 12, and 24 hours following surgery. Total analgesic consumption within the first 24 hours will also be recorded.
Participants will be categorized based on their smartphone addiction scores, and postoperative pain outcomes and analgesic consumption will be compared between groups. Additionally, correlation analyses will be performed to explore the association between smartphone addiction levels and perceived postoperative pain.
Sample size was calculated using an effect size derived from a previous study reporting a correlation coefficient of rho = 0.292 between problematic phone use and perceived pain. With a significance level of 0.05 and a statistical power of 80%, a minimum of 91 participants were required. To compensate for an anticipated dropout rate of approximately 10%, the final planned sample size is 100 participants.
Type d'étude
Inscription (Estimé)
Contacts et emplacements
Lieux d'étude
-
-
Tokat Province
-
Tokat Province, Tokat Province, Turquie (Türkiye), 60100
- Tokat Gaziosmanpasa University
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
Méthode d'échantillonnage
Population étudiée
Sample size was calculated using an effect size derived from a previous study reporting a correlation coefficient of rho = 0.292 between problematic phone use and perceived pain. With a significance level of 0.05 and a statistical power of 80%, a minimum of 91 participants were required. To compensate for an anticipated dropout rate of approximately 10%, the final planned sample size is 100 participants.
La description
Inclusion Criteria:
- Adults aged 18-45 years
- Scheduled for elective primary rhinoplasty under general anesthesia
- ASA physical status I-II
- Ability to provide informed consent
Exclusion Criteria:
- History of psychiatric disorders (diagnosed anxiety, depression, bipolar disorder, psychosis)
- Use of chronic analgesic, opioid, sedative, or psychotropic medication
- Previous rhinoplasty or combined surgeries
- Neurological disorders affecting pain perception
- Communication difficulties or inability to complete questionnaires
- Chronic pain syndromes (e.g., fibromyalgia, chronic back pain)
- Intraoperative complications requiring deviation from standard anesthesia
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Modèles d'observation: COHORT
- Perspectives temporelles: PROSPECTIVE
Cohortes et interventions
Groupe / Cohorte |
|---|
|
Patients undergoing elective rhinoplasty
This cohort includes adult patients aged 18-45 years with ASA physical status I-II who are scheduled to undergo elective rhinoplasty under general anesthesia. All participants will complete preoperative assessments, including demographic data and validated Turkish versions of the Smartphone Application-Based Addiction Scale and the Nomophobia Questionnaire (NMP-Q). Postoperative pain scores (VAS) will be recorded at 1, 6, 12, and 24 hours following surgery, along with total analgesic consumption within the first 24 hours. No interventions will be applied as part of the study; the cohort will be observed prospectively |
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Postoperative Pain Score (VAS)
Délai: 1st, 6th, 12th, and 24th postoperative hours.
|
Pain intensity measured using the Visual Analog Scale (0-10) |
1st, 6th, 12th, and 24th postoperative hours.
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Total Analgesic Consumption
Délai: 24 hours postoperatively
|
The total analgesic consumption within the first 24 postoperative hours, including tramadol administered through patient-controlled analgesia (PCA). |
24 hours postoperatively
|
Collaborateurs et enquêteurs
Parrainer
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Achèvement primaire (Estimé)
Achèvement de l'étude (Estimé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Mots clés
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- 25-MOBAEK-374
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Description du régime IPD
The data supporting the findings of this study are available from the corresponding author upon reasonable request. Interested researchers may contact the corresponding author via email and provide a brief description of their intended use.
Type d'informations de prise en charge du partage d'IPD
- PROTOCOLE D'ÉTUDE
- SÈVE
- CIF
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .